Table 1 Patient clinical characteristics.
From: Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
Characteristics | All patients (N = 103) |
|---|---|
Age (years) | Â |
Median (range) | 64 (38–82) |
Gender (%) | Â |
Male | 67 (65%) |
Female | 36 (35%) |
Smoking status (%) | Â |
Yes | 61 (59%) |
No | 42 (41%) |
Differentiation (%) | Â |
Info available | 19 (18%) |
Not available | 84 (82%) |
Histology (%) | Â |
Adenocarcinoma | 60 (58%) |
Squamous cell carcinoma | 38 (37%) |
Atypical carcinoid | 1 (1%) |
Adenosquamous carcinoma | 1 (1%) |
Large cell neuroendocrine carcinoma | 3 (3%) |
pTMN stage (%) | Â |
I | 12 (10%) |
IIb | 41 (40%) |
IIIa | 48 (47%) |
IV | 2 (2%) |
T stage (%) | Â |
T1–T3 | 95 (92%) |
T4 | 8 (8%) |
N stage (%) | Â |
N0–N1 | 68 (66%) |
N2 | 35 (34%) |
Adjuvant therapy (%) | Â |
Chemotherapy | 72 (70%) |
Chemoradiotherapy | 1 (1%) |
Targeted therapy | 5 (5%) |
Chemotherapy + targeted therapy | 2 (2%) |
No | 23 (22%) |
Recurrence (%) | Â |
No recurrence | 66 (64%) |
Locoregional recurrence | 11 (10%) |
Lymph mode | 8 (8%) |
lung | 7 (7%) |
Brain | 3 (3%) |
Other | 8 (8%) |
